Based on the guidance received from the fda letter to healthcare provider, "potential risk of infection during cardiac surgery when using the cardioquip modular cooler-heater device" dated september 30th, 2020 and device concerns raised in the letter, we are submitting a voluntary report.On 3/20/24 (b)(6) medical center identified bioburden on the cardioquip machine.The machines were removed immediately from use and sequestered while the machines were evaluated for contamination by the manufacturer by heterotrophic plate count (micro culture).Lab cultures resulted in 507,000 mpn/ml which is well above the accepted value of <100 mpn/ml.The machine underwent full annual preventive maintenance and sanitation with manufacturer's approved disinfectant and re-cultured.The re-culture returned within normal limits and the machine was approved to be returned back to service.No patients were exposed and no gaps have been identified with maintenance at this point in time but a gap analysis is underway.The serial number for the unit is (b)(6).
|